Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2000 Sep;92(9):445–449.

Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patients.

S O Asbell 1, K C Raimane 1, A T Montesano 1, K L Zeitzer 1, M D Asbell 1, S Vijayakumar 1
PMCID: PMC2608532  PMID: 11052458

Abstract

Prostate cancer in African Americans is more aggressive and common than in any other racial group. An endocrine mechanism has been proposed to account for this racial difference. However, androgen levels in African-American elderly normal subjects and prostate cancer patients have been insufficiently studied. Because the Albert Einstein Medical Center (AEMC) has a large African-American population, we could contribute racial data from which observations could be made within this study and in past and future studies. Blood from 38 screened men (mean age 65) with prostate-specific antigen (PSA) less than 4 ng/mL and normal rectal examination seen at the AEMC Cancer Center was studied using standard radioimmunoassays. The blood samples also served as our control. Our experimental group consisted of 51 prostate cancer patients (mean age 71 years), all of whom had nonmetastatic prostate cancer. Subjects were categorized by cancer status, race, and age group. In our screened subjects, PSA, testosterone, and dihydrotestosterone were not higher in African Americans than in whites. Furthermore, our prostate cancer patients demonstrated no significant racial variation for PSA, testosterone, and dihydrotestosterone. Our data also did not indicate any correlation between PSA and androgen levels in our cancer patients. In our population of elderly men, no racial differences in androgen levels were found. Androgen levels did not correlate with PSA levels in prostate cancer patients.

Full text

PDF
445

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdalla I., Ray P., Ray V., Vaida F., Vijayakumar S. Comparison of serum prostate-specific antigen levels and PSA density in African-American, white, and Hispanic men without prostate cancer. Urology. 1998 Feb;51(2):300–305. doi: 10.1016/s0090-4295(97)00617-1. [DOI] [PubMed] [Google Scholar]
  2. Abdalla I., Ray P., Vijayakumar S. Race and serum prostate-specific antigen levels: current status and future directions. Semin Urol Oncol. 1998 Nov;16(4):207–213. [PubMed] [Google Scholar]
  3. Andersson S. O., Adami H. O., Bergström R., Wide L. Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study. Br J Cancer. 1993 Jul;68(1):97–102. doi: 10.1038/bjc.1993.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Asbell S. O., Vijayakumar S. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Prostate. 1997 Apr 1;31(1):42–46. doi: 10.1002/(sici)1097-0045(19970401)31:1<42::aid-pros7>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  5. Carlström K., Eriksson A., Stege R., Rannevik G. Relationship between serum testosterone and sex hormone-binding globulin in adult men with intact or absent gonadal function. Int J Androl. 1990 Feb;13(1):67–73. doi: 10.1111/j.1365-2605.1990.tb00961.x. [DOI] [PubMed] [Google Scholar]
  6. Eastham J. A., May R. A., Whatley T., Crow A., Venable D. D., Sartor O. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst. 1998 May 20;90(10):756–760. doi: 10.1093/jnci/90.10.756. [DOI] [PubMed] [Google Scholar]
  7. Ellis L., Nyborg H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids. 1992 Feb;57(2):72–75. doi: 10.1016/0039-128x(92)90032-5. [DOI] [PubMed] [Google Scholar]
  8. George F. W., Russell D. W., Wilson J. D. Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8044–8047. doi: 10.1073/pnas.88.18.8044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hsing A. W., Comstock G. W. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993 Jan-Feb;2(1):27–32. [PubMed] [Google Scholar]
  10. Lamb J. C., Levy M. A., Johnson R. K., Isaacs J. T. Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. Prostate. 1992;21(1):15–34. doi: 10.1002/pros.2990210103. [DOI] [PubMed] [Google Scholar]
  11. Morgan T. O., Jacobsen S. J., McCarthy W. F., Jacobson D. J., McLeod D. G., Moul J. W. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. 1996 Aug 1;335(5):304–310. doi: 10.1056/NEJM199608013350502. [DOI] [PubMed] [Google Scholar]
  12. Moul J. W., Sesterhenn I. A., Connelly R. R., Douglas T., Srivastava S., Mostofi F. K., McLeod D. G. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995 Oct 25;274(16):1277–1281. [PubMed] [Google Scholar]
  13. Ross R. K., Bernstein L., Lobo R. A., Shimizu H., Stanczyk F. Z., Pike M. C., Henderson B. E. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992 Apr 11;339(8798):887–889. doi: 10.1016/0140-6736(92)90927-u. [DOI] [PubMed] [Google Scholar]
  14. Ross R., Bernstein L., Judd H., Hanisch R., Pike M., Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986 Jan;76(1):45–48. [PubMed] [Google Scholar]
  15. Tenover J. S. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992 Oct;75(4):1092–1098. doi: 10.1210/jcem.75.4.1400877. [DOI] [PubMed] [Google Scholar]
  16. Vijayakumar S., Karrison T., Weichselbaum R. R., Chan S., Quadri S. F., Awan A. M. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):541–545. [PubMed] [Google Scholar]
  17. Vijayakumar S., Quadri S. F., Dong L., Ignacio L., Kathuria I. N., Sutton H., Halpern H. Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer. J Natl Med Assoc. 1995 Nov;87(11):813–819. [PMC free article] [PubMed] [Google Scholar]
  18. Vijayakumar S., Weichselbaum R., Vaida F., Dale W., Hellman S. Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am. 1996 Jul-Aug;2(4):225–233. [PubMed] [Google Scholar]
  19. Wilson D. W., Harper M. E., Jensen H. M., Ikeda R. M., Richards G., Peeling W. B., Pierrepoint C. G., Griffiths K. A prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation. Prostate. 1985;7(2):131–141. doi: 10.1002/pros.2990070203. [DOI] [PubMed] [Google Scholar]
  20. Wu A. H., Whittemore A. S., Kolonel L. N., John E. M., Gallagher R. P., West D. W., Hankin J., Teh C. Z., Dreon D. M., Paffenbarger R. S., Jr Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):735–741. [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES